Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-I7 after CAR-T in Relapsed/Refractory Large B-cell Lymphoma
NCT05075603Phase 1Completed
- Sponsor
- NeoImmuneTech
- Start
- Jul 2021
- Primary completion
- Dec 2024
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of efineptakin alfa in diffuse large B-cell lymphoma (DLBCL), sponsored by NeoImmuneTech. Primary endpoints: Incidence, Nature, and Severity of Adverse Events, Incidence and Nature of Dose-Limiting Toxicities and 1 more. Started Jul 2021; status: completed.
02
Drugs
efineptakin alfa
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05075603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075603.